Howard Trachtman, MD

A four-category classification and a growing list of implicated genes still leave real gaps in understanding FSGS, but sparsentan's approval marks the first therapy built specifically around its dual-injury mechanism.

FSGS is not a single disease but a shared pattern of podocyte injury that spans every age group, from pediatric to adult nephrology, demanding equal attention regardless of a patient's age or underlying cause.